Stockreport

AEON Biopharma Reports First Quarter 2024 Financial Results

AEON Biopharma, Inc. Class A  (AEON) 
PDF – Ongoing analysis of interim data from the Phase 2 study of ABP-450 in chronic migraine, which did not achieve its primary or secondary endpoints – – Evaluating next [Read more]